<a href="https://laohu8.com/S/CRBU">Caribou Biosciences</a> Inc. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Non-GAAP Net Loss at $32.8M, EPS at $0.35; Licensing Revenue Drops to $2.7M
Caribou Biosciences Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its financial results for the second quarter of 2025. The company reported a net loss of $54.1 million, compared to a net loss of $37.7 million for the same period in 2024. Revenue from licensing and collaboration agreements reached $2.7 million, down from $3.5 million in the previous year. Caribou's non-GAAP net loss, which excludes $21.3 million of non-cash impairment charges, was $32.8 million. The company ended the quarter with $183.9 million in cash, cash equivalents, and marketable securities, a decrease from $249.4 million at the end of 2024. Despite this, Caribou expects its current financial resources to sustain its operating plan into the second half of 2027. In addition to financial figures, Caribou provided updates on its oncology clinical programs, CB-010 and CB-011, with significant data disclosures anticipated in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511203-en) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.